Pharma Firms Urged To Push For Post-Brexit Regulatory Equivalence Deal
Executive Summary
A mutual recognition agreement between the UK and EU on equivalence of regulatory procedures and processes could provide pharmaceutical companies with some stability and continuity post-Brexit – and save them some money.
You may also be interested in...
Japan Issues Strong Warning Over Brexit
Uncertainty is bad for business and can deter investment, warns Japan in relation to eventual talks on the UK’s exit from the EU. Japan’s preferred Brexit outcome? For the UK to keep both EU law and the European Medicines Agency.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.